Women's Cancer Research Network
Welcome,         Profile    Billing    Logout  
 34 Trials 
44 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chambers, Setsuko K
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

Terminated
3
20
Canada, US, RoW
Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo
Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
09/23
09/23
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076)

Recruiting
3
186
US
olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Genelux Corporation, GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
08/25
10/26
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
Konecny, Gottfried E
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCI-2018-01550, NCT03732950: Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

Active, not recruiting
2
5
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Jonsson Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
12/23
03/25
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
NCT04469764: Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Recruiting
2
32
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Letrozole, CGS 20267, Femara
Jonsson Comprehensive Cancer Center, Eli Lilly and Company
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
07/25
07/26
OPAL, NCT03574779: A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

Hourglass Oct 2019 - Dec 2019 : Proof-of-concept data from OPAL trial in combination with dostarlimab and Avastin for 2L+ PROC ovarian cancer
Active, not recruiting
2
125
Europe, Canada, US, RoW
Niraparib, ZEJULA, TSR-042, Bevacizumab, Avastin, Carboplatin, Paclitaxel
Tesaro, Inc.
Ovarian Neoplasms
08/25
04/27
CATALINA-2, NCT06690775: a Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Recruiting
2
230
US
TORL-1-23, Pegfilgrastim (drug)
TORL Biotherapeutics, LLC, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
10/27
12/27
PRO1184-001, NCT05579366: Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ )

Recruiting
1/2
404
US, RoW
Rina-S, PRO1184, Rinatabart sesutecan, GEN1184, Carboplatin, Bevacizumab, Pembrolizumab
Genmab
Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer
04/26
10/26
IMGN151-1001, NCT05527184: First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Recruiting
1
423
US
IMGN151
AbbVie
Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer
02/27
02/27
STRO-002-GM1, NCT03748186: Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Completed
1
136
Europe, US
STRO-002
Sutro Biopharma, Inc.
Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
06/24
06/24
TRIO-049, NCT05103683: First in Human Study of TORL-1-23 in Participants With Advanced Cancer

Recruiting
1
90
US
TORL-1-23
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
11/24
11/25
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Banerjee, Susana
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting
3
294
Europe, US, RoW
AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol
Advenchen Laboratories, LLC, Advenchen Laboratories, LLC
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
10/24
12/24
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
ATARI, NCT04065269: ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

Recruiting
2
174
Europe, Canada
Ceralasertib, AZD6738, Olaparib, Durvalumab, MEDI4736
Institute of Cancer Research, United Kingdom, Cancer Research UK, AstraZeneca
Gynaecological Cancers
04/26
04/26
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Recruiting
2
160
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC
Seagen Inc.
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms
05/26
05/28
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
FRAME, NCT03875820: Phase I Trial of Defactinib and VS-6766.

Checkmark Data from FRAME trial in combination with VS-6766 for Ovarian Cancer at ESMO 2021
Sep 2021 - Sep 2021: Data from FRAME trial in combination with VS-6766 for Ovarian Cancer at ESMO 2021
Checkmark Data from FRAME trial in combination with VS-6766 for Ovarian Cancer
Sep 2020 - Sep 2020: Data from FRAME trial in combination with VS-6766 for Ovarian Cancer
Checkmark Data from FRAME trial in combination with VS-6766 for solid tumors at AACR 2020
More
Active, not recruiting
1
87
Europe
VS-6766, RO5126766, CH5126766, Defactinib, VS-6063
Institute of Cancer Research, United Kingdom, Verastem, Inc.
NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma, Pancreatic Cancer
04/23
10/23
SL03-OHD-105, NCT05483933: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers

Active, not recruiting
1
86
Europe, Canada, US
Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV
Shattuck Labs, Inc.
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
11/24
11/24
NXP800-101, NCT05226507: A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer

Recruiting
1
61
Europe, US
NXP800
Nuvectis Pharma, Inc., European Network for Gynaecological Oncological Trial Groups, Gynecologic Oncology Group Foundation
Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation
05/25
12/25
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Oaknin, Ana
BEATcc, NCT03556839 / 2018-000367-83: Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

Active, not recruiting
3
410
Europe, Japan, US
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Cisplatin/Carboplatin, Paclitaxel
Grupo Español de Investigación en Cáncer de Ovario, ARCAGY/ GINECO GROUP, Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies, MaNGO, NSGO, Japanese Gynecologic Oncology Group, Gynecologic Oncology Group Foundation, AGO Study Group, Apices Soluciones S.L., Hoffmann-La Roche
Carcinoma of the Cervix, Stage IVB
08/25
08/25
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
ATOMICC, NCT03833479 / 2018-002155-15: TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

Active, not recruiting
2
134
Europe, RoW
No Further Treatment, TSR-042
Grupo Español de Investigación en Cáncer de Ovario, Apices Soluciones S.L., GSK/TESARO
Cervical Cancer, Advanced Cancer
12/25
12/25
SURPASS-3, NCT05601752 / 2022-003176-16: ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer

Active, not recruiting
2
66
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
Adaptimmune, GOG Foundation
Ovarian Cancer
08/26
08/26
EDO-S101-1002, NCT03345485 / 2020-004246-11: Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

Completed
1/2
71
Europe, Canada, US
Tinostamustine 60mg/m2 over 30min, EDO-S101, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, EDO-S101., Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
Mundipharma Research Limited, Mundipharma Research Limited
Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
07/22
03/23
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
SL03-OHD-105, NCT05483933: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers

Active, not recruiting
1
86
Europe, Canada, US
Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV
Shattuck Labs, Inc.
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
11/24
11/24
NCT06431594: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Recruiting
1
240
Europe, Canada, Japan, US, RoW
GSK5733584
GlaxoSmithKline
Solid Tumors, Neoplasms
10/26
06/27
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Frosig, Trevor
NCT05300048: Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Active, not recruiting
1
68
US
Serabelisib, Insulin Suppressing Diet, Nab paclitaxel
Faeth Therapeutics
Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation
09/24
09/24
realMIND, NCT04981795: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Recruiting
N/A
100
US
Tafasitamab
Incyte Corporation, Iqvia Pty Ltd
Diffuse Large B-cell Lymphoma
10/25
08/26
Perkins, Christopher
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
SGNALPV-001, NCT05229900: A Study of SGN-ALPV in Advanced Solid Tumors

Terminated
1
43
Europe, Canada, US
SGN-ALPV
Seagen Inc.
Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Gastroesophageal Junction Carcinoma, Uterine Cervical Neoplasms, Testicular Neoplasms
12/23
12/23

Download Options